NEW YORK, June 3, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, has appointed Gregory M. Sullivan, M.D. Chief Medical Officer, a newly created position. He will oversee medical aspects of the company's clinical research and development program, which is focused on common disorders of the central nervous system (CNS). Dr. Sullivan brings to Tonix more than two decades of experience in the diagnosis, treatment and neurobiology of anxiety and mood disorders. Dr. Sullivan has served on the company's Scientific Advisory Board since 2010 and additionally has been a consultant to the company since 2013.
"We are very pleased to welcome Greg to the Tonix management team as we anticipate the completion of BESTFIT - a potential pivotal trial evaluating TNX-102 SL as a treatment for fibromyalgia - later this year as well as the upcoming initiation of a Phase 2 trial evaluating TNX-102 SL for the treatment of military-related post-traumatic stress disorder (PTSD)," said Seth Lederman, M.D., Chairman and Chief Executive Officer of Tonix. "Greg's unique combination of medical and scientific expertise is tremendously valuable to the advancement of our pipeline of CNS candidates."
Dr. Sullivan's career includes experience as an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center, a Research Scientist at the New York State Psychiatric Institute (NYSPI), and as a practicing psychiatrist. His areas of expertise include the diagnosis, treatment and neurobiology of anxiety and mood disorders, including PTSD. As Principal Investigator and Co-Investigator on several human studies of PTSD, Dr. Sullivan has administered the recruitment, biological assessments, treatment, and safety of participants with PTSD in clinical trials of the disorder. He has served as a member of the Institutional Review Board of the NYSPI since 2009. He has published more than 50 articles and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonergic receptor expression in bipolar depression, PTSD and panic disorder. He is a recipient of grants from the National Institute of Mental Health, the Anxiety Disorders Association of America, and the American Foundation for Suicide Prevention. Dr. Sullivan received his medical doctorate from the College of Physicians & Surgeons at Columbia University and completed his residency training in psychiatry at Columbia University Medical Center. He completed a two-year National Institutes of Health-sponsored research fellowship in anxiety and affective disorders before joining the faculty at Columbia.